AI-Powered Pathology Can Radically Enhance Diagnostic Accuracy and Treatment Selection

PathAI (Boston, MA, USA) and Cleveland Clinic (Cleveland, OH, USA) have entered into a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas. The collaboration will enable the digitization of hundreds of thousands of pathology specimens, creating millions of whole slide images across multiple disease areas. By linking this digital pathology data with clinical and molecular data, Cleveland Clinic and PathAI will have a rich multi-modal dataset to conduct research using PathAI’s technology platform and menu of pathology algorithms. The partnership also will provide educational opportunities for Cleveland Clinic faculty and trainees, with the goal of enabling the development and usage of AI-powered pathology diagnostics to improve patient care.

Cleveland Clinic will become an equity holder in PathAI as part of this agreement. PathAI will gain access to the digitized pathology slides to develop and improve its AI-powered algorithms, as well as clinical information for research and validation purposes all of which have been de-identified to protect patient privacy. Cleveland Clinic’s medical team will provide expertise to ensure algorithms are fit-for-purpose in both clinical and research settings.

“Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection,” said Dr. Brian Rubin, chair of Pathology and Laboratory Medicine Institute at Cleveland Clinic. “By doing this work, we’re able to maximize the value of machine learning for our patients and fuel deeper innovation that can result in better outcomes.”

“This exciting collaboration accelerates PathAI’s mission to provide precision pathology for everyone. Cleveland Clinic is the ideal partner, with its many leading clinicians, educators, and researchers who are committed to transforming patient care across disease areas,” said Dr. Andy Beck, CEO of PathAI. “We see an incredible opportunity to accelerate innovation in precision pathology and to use our strengths to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research.”

Related Links:
PathAI
Cleveland Clinic